Mesa Laboratories (NASDAQ: MLAB) director lifts stake to 6,298 shares
Rhea-AI Filing Summary
Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share. Following this transaction, Tripeny’s directly held stake increased to 6,298 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 900 shares
Net Buy
1 txn
Insider
Tripeny R Tony
Role
Director
Bought
900 shs ($102K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 900 | $113.69 | $102K |
Holdings After Transaction:
Common Stock — 6,298 shares (Direct)
Key Figures
Shares Purchased: 900 shares
Purchase Price: $113.69 per share
Shares Owned After: 6,298 shares
+2 more
5 metrics
Shares Purchased
900 shares
Common stock bought on 2026-08-13 in a non-derivative transaction
Purchase Price
$113.69 per share
Price for the 900 common shares acquired on 2026-08-13
Shares Owned After
6,298 shares
Total directly held Mesa Laboratories common shares after the transaction
Net Buy Shares
900 shares
Net buy direction across all reported transactions in this Form 4
Buy Transactions Count
1
Number of buy transactions reported for this date
Key Terms
Common Stock, non-derivative, Purchase in open market or private transaction
3 terms
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
non-derivative financial
"transaction_type: "non-derivative""
Purchase in open market or private transaction financial
"transaction_code_description: "Purchase in open market or private transaction""
FAQ
What insider transaction did MLAB director R. Tony Tripeny report on this Form 4?
R. Tony Tripeny reported a purchase of 900 shares of Mesa Laboratories common stock on 2026-08-13. The transaction was reported as a non-derivative, open-market or private purchase at a price of $113.69 per share, increasing his direct holdings.
Was the recent MLAB insider purchase by R. Tony Tripeny made under a Rule 10b5-1 plan?
The transaction was not indicated as under a Rule 10b5-1 plan. The Form 4’s plan-status indicator is set to false, meaning the filer did not check the box affirming that the reported trade was executed pursuant to a pre-arranged trading plan.
What type of security did R. Tony Tripeny acquire in the latest MLAB Form 4 filing?
He acquired common stock of Mesa Laboratories in a non-derivative transaction. The Form 4 specifically lists the security title as common stock and categorizes the transaction type as non-derivative, confirming it was a direct share purchase rather than a derivative security exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
